COMMUNIQUÉS West-GlobeNewswire

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
24/03/2026
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN [...]
DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris
24/03/2026
Châtillon, France, le 24 mars (22 :30 CET) 2026 DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris Les modifications sont entrées en vigueur le lundi 23 mars [...]
Spectral AI Announces 2025 Fourth Quarter and Full Year Financial Results and Introduces Revenue Guidance for 2026
24/03/2026
Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million Cash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
24/03/2026
Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from Phase II trial [...]
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
24/03/2026
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
Glass House Brands Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in Glass House history [...]
Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026
24/03/2026
NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
24/03/2026
Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports [...]
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal [...]
BioCardia Reports 2025 Business Highlights and Financial Results
24/03/2026
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
24/03/2026
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
24/03/2026
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total [...]
CROSSJECT publie ses résultats financiers 2025 et confirme le renforcement de sa trajectoire opérationnelle, industrielle et financière
24/03/2026
DIJON, France – 24 mars 2026 (18H30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie [...]
ATI Advisory Designs Medicare-Based Model to Support Needs of the “Overlooked Middle;” Actuarial Analysis Projects Over $500 Million in Savings
24/03/2026
Newly designed model concept demonstrates viable pathway to deliver targeted home- and community-based services within Traditional Medicare; projected to reduce Medicare spending Washington, DC, March 24, 2026 (GLOBE [...]
Tatwa Integrative Medicine Establishes Itself as Europe's Reference for Amazonian Floral Essences and Launches Its 10th Vibratory Elixir
24/03/2026
The Colombian-Swiss company Tatwa Integrative Medicine is cementing its leadership in the integrative medicine and wellness market with the launch of Tabaco, a floral essence for clarity, energetic protection and inner [...]
SK pharmteco et Prozomix annoncent une collaboration stratégique visant à renforcer leurs capacités en matière de biocatalyse pour la fabrication de médicaments à l’échelle mondiale
24/03/2026
RANCHO CORDOVA, Californie, 24 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco , une organisation mondiale de premier plan spécialisée dans le développement et la fabrication sous contrat (CDMO) et Prozomix , pionnière dans [...]
Leo International Precision Health AG approves cash capital increase excluding subscription rights
24/03/2026
Leo International Precision Health AG / Keyword: Capital measures / Capital increase Leo International Precision Health AG approves cash capital increase excluding subscription rights 24. Mar 2026 / 17:44 CET/CEST [...]
Adjustment of guidance for 2025/26
24/03/2026
ANNOUNCEMENT NO. 303 24 March 2026 Adjustment of guidance for 2025/26 Over the past period, ChemoMetec's most important market, the North American market for cell and gene therapy, has been affected by three factors [...]

Pages